Karl D. Lewis, MD - Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Go online to PeerView.com/SDX860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The arrival of immunotherapy in basal cell carcinoma (BCC)
increases the potential for successful treatment outcomes—are you
prepared to address several practical questions related to
selection and sequencing of immunotherapy, safety management, and
patient monitoring? In this activity, based on a recent PeerView
Live Seminars & Tumor Board educational event held at the 2022
American Society of Clinical Oncology Annual Meeting, our expert
panel links the evidence supporting the use of immunotherapy in
locally advanced and metastatic BCC with case-based teaching
designed to mimic the collaborative aspects of real-world,
multidisciplinary tumor boards, ultimately illustrating how
checkpoint inhibitors can be integrated into the care of patients
with BCC. Leverage the power of immunotherapy to improve clinical
outcomes for your patients with advanced BCC! Upon completion of
this activity, participants should be better able to: Cite the
rationale, therapeutic role, and current evidence and guidelines
supporting the use of immune checkpoint inhibitors (ICIs) in the
management of advanced BCC; Integrate novel immunotherapy options
into the management of appropriate patients with advanced BCC in
consultation with the wider management team; and Employ proactive,
team-based approaches to recognize, mitigate, and manage potential
immune-related adverse events in patients receiving ICI therapy for
advanced BCC.